First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve

被引:154
|
作者
Rodriguez-Grunert, Leonardo [1 ]
Neto, Manoel Passos Galvao [2 ]
Alamo, Munir [1 ]
Ramos, Almino Cardoso [2 ]
Baez, Percy Brante [1 ]
Tarnoff, Michael [3 ]
机构
[1] Hosp Dipreca, Ctr Cirugia Obesidad, Santiago, Chile
[2] Gastro Obeso Ctr, Sao Paulo, Brazil
[3] Tufts Univ New England Med Ctr, Dept Surg, Boston, MA USA
关键词
Bariatric; Endoluminal; Diabetes; Obesity; Duodenum;
D O I
10.1016/j.soard.2007.07.012
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: We report the first human experience with an endoscopic duodenal-jejunal bypass sleeve (DJBS) in a community hospital. Methods: The DJBS is a 60-cm sleeve anchored in the duodenum to create a duodenal-jejunal bypass. In a 12-patient prospective, open-label, single-center, 12-week study, the device was endoscopically implanted, left in situ, and retrieved. The study included 5 men and 7 women, with a mean body mass index of 43 kg/m(2). Of the 12 patients, 4 had type 2 diabetes. The primary endpoints were the incidence and severity of adverse events. The secondary outcomes included the percentage of excess weight loss and changes in co-morbid status. Results: The DJBS was endoscopically delivered and retrieved in all patients (mean implant/explant time of 26.6 and 43.3 min, respectively). Of the 12 patients, 10 were able to maintain the device for 12 weeks and 2 underwent explantation after 9 days secondary to poor device placement. Several self-limited adverse events were possibly or definitely related to the device, including 6 episodes of abdominal pain, 18 of nausea, and 16 of vomiting, mainly within 2 weeks of implantation. Two partial pharyngeal tears occurred during explantation. Implant site inflammation was encountered in all patients. No device-related event was considered severe. The average percentage of excess weight loss for the 10 patients with the device in place for 12 weeks was 23.6%, with all patients achieving at least 10% excess weight loss. All 4 diabetic patients had normal fasting plasma glucose levels without hypoglycemic medication for the entire 12 weeks. Of these 4 patients, 3 had decreased hemoglobin A(1C) of >=.5% by week 12. Conclusion: The DJBS can be safely delivered and removed endoscopically and left in situ for 12 weeks. The device had a favorable safety and encouraging efficacy profile. Randomized prospective trials are warranted. (Surg Obes Relat Dis 2008;4:55-59.) (C) 2008 American Society for Metabolic and Bariatric Surgery. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [1] Chronic in-vivo experience with an endoscopically delivered and retrieved duodenal-jejunal bypass sleeve in a porcine model
    Tarnoff, M.
    Shikora, S.
    Lembo, A.
    Gersin, K.
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2008, 22 (04): : 1023 - 1028
  • [2] Chronic in-vivo experience with an endoscopically delivered and retrieved duodenal-jejunal bypass sleeve in a porcine model
    M. Tarnoff
    S. Shikora
    A. Lembo
    K. Gersin
    Surgical Endoscopy, 2008, 22 : 1023 - 1028
  • [3] Endoscopic duodenal-jejunal bypass sleeve: First human experience on a safety trial
    Rodriguez, Leonardo
    Ramos, Almino
    Neto, Manoel Galvao
    Alamo, Munir
    Brante, Percy
    Reyes, Eliana
    Tarnoff, Michael
    OBESITY SURGERY, 2007, 17 (08) : 1042 - 1042
  • [4] SCIENCE AND TECHNOLOGY WATCH An Endoscopically Placed Duodenal-Jejunal Bypass Sleeve
    Ricaurte, Eduard M.
    Rios-Tejada, Francisco
    Flores-Rojas, Karina
    AVIATION SPACE AND ENVIRONMENTAL MEDICINE, 2013, 84 (06): : 646 - 647
  • [5] ENDOSCOPICALLY DELIVERED DUODENAL-JEJUNAL BYPASS LINER TO TREAT TYPE 2 DIABETES IN OBESE PATIENTS
    Curcio, G.
    Casu, A.
    Traina, M.
    Colanino, M. Ziino
    Tuzzolino, F.
    Vizzini, G.
    Gridelli, B.
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : S143 - S143
  • [6] Duodenal-jejunal bypass with sleeve gastrectomy versus the sleeve gastrectomy procedure alone: the role of duodenal exclusion
    Lee, Wei-Jei
    Almulaifi, Abdullah M.
    Tsou, Jun-Juin
    Ser, Kong-Han
    Lee, Yi-Chih
    Chen, Shu-Chun
    SURGERY FOR OBESITY AND RELATED DISEASES, 2015, 11 (04) : 765 - 770
  • [7] Consistent Improvement of Metabolic Parameters in Obese Patients with Type 2 Diabetes by the Endoscopically Delivered Duodenal-Jejunal Bypass Liner (DJBL)
    Laubner, Katharina
    Perakakis, Nikolaos
    Potasso, Laura
    Schwacha, Henning
    Seufert, Jochen
    DIABETES, 2015, 64 : A556 - A556
  • [8] Duodenal-jejunal bypass sleeve: A totally endoscopic device for the treatment of morbid obesity
    Gersin, Keith S.
    Keller, Jennifer E.
    Stefanidis, Dimitrios
    Simms, Connie S.
    Abraham, Delois D.
    Deal, Stephen E.
    Kuwada, Timothy S.
    Heniford, B. Todd
    SURGICAL INNOVATION, 2007, 14 (04) : 275 - 278
  • [9] THE DUODENAL-JEJUNAL BYPASS SLEEVE (ENDOBARRIER®) INDUCES TRANSIENT CHANGES IN THE STOOL MICROBIOTA
    McMaster, Jessica J.
    Shanahan, Erin R.
    Rich, Graeme
    Veronique, Chachay
    Macdonald, Graeme
    Morrison, Mark
    Holtmann, Gerald J.
    GASTROENTEROLOGY, 2018, 154 (06) : S652 - S652
  • [10] Mechanisms of Action for Weight Reduction in Patients Treated with a Duodenal-Jejunal Bypass Sleeve
    Mcmaster, Jessica Jade
    Rich, Graeme G.
    Shanahan, Erin R.
    Do, Anh T.
    Fletcher, Linda M.
    Kutyla, Marguerite J.
    Tallis, Caroline
    Chachay, Veronique S.
    Morrison, Mark
    Macdonald, Graeme A.
    Holtmann, Gerald J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 213 - 213